Form 4: Ionis Pharmaceuticals Executive Sells Shares

C. Frank Bennett, EVP and Chief Scientific Officer at Ionis Pharmaceuticals, reported transactions involving the sale of company stock and a transfer to a trust.

Summary

• C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, engaged in several stock transactions on July 7, 2026.
• He sold 5,536 shares of common stock at a weighted average price of $83.579, with individual sales ranging from $83.070 to $84.065.
• Additionally, 15,000 shares were sold at a weighted average price of $85.462, with individual sales ranging from $85.015 to $85.730.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on March 31, 2026.
• Bennett also transferred 15,000 shares of common stock from direct to indirect ownership within the Clarence Frank Bennett TTEE Bennett Living Trust, of which he is a co-trustee.
• A Restricted Stock Unit vested on January 15, 2026, and was paid out in 15,000 shares of Ionis common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant volume of shares sold by a key executive, despite the use of a Rule 10b5-1 plan.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to stock disposition.
• The vesting of Restricted Stock Units suggests continued incentive alignment for management.
• The transfer to a trust indicates estate planning or long-term wealth management strategies.

Negatives

• Significant sale of company stock by a key executive, totaling 20,536 shares (5,536 + 15,000 sold).
• The sales occurred at prices between $83.070 and $85.730, potentially indicating the executive's view on the stock's current valuation.

Risks

• Insider selling can sometimes be interpreted negatively by the market, potentially impacting investor sentiment.
• The Rule 10b5-1 plan, while providing a defense against insider trading allegations, still represents a disposition of shares by management.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing, which primarily reports past transactions.

Management Comments

• Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026.
• The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) and (4).

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors, detailing changes in their beneficial ownership of company stock. While this filing details standard transactions, significant sales by key executives can sometimes be a signal to the market, though the presence of a Rule 10b5-1 plan mitigates concerns about opportunistic trading.

Related Party Transactions

• Transfer of 15,000 shares of common stock from direct ownership to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust, of which the reporting person is the co-trustee with spouse.

Stakeholder Impact

• Shareholders: May interpret the executive's stock sales as a signal of valuation or future performance expectations, potentially influencing trading decisions.
• Employees: The vesting of RSUs indicates continued incentive programs for management.
• Management: The transactions reflect personal financial planning and adherence to trading policies.

Next Steps

• The reporting person may be required to provide further details on specific sale prices upon request from Ionis Pharmaceuticals, Inc., shareholders, or the SEC staff.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Restricted Stock Unit, C. Frank Bennett, EVP Chief Scientific Officer, Beneficial Ownership